<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3301808</article-id><article-id pub-id-type="publisher-id">cc480</article-id><article-id pub-id-type="doi">10.1186/cc480</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Effects of stress-dose hydrocortisone therapy in septic shock (part III): monocyte HLA-DR expression and blood interferon-? concentration. Preliminary results of a double blinded, randomized, placebo-controlled cross-over study</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>B&#x000f6;hnke</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Schulz</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Keh</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Pettersson</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Weber-Carstens</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Ahlers</surname><given-names>O</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Bercker</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Berg</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Risse</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Nordmann</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Falke</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Gerlach</surname><given-names>H</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Clinic of Anaesthesiology and Intensive Care Medicine, Charit&#x000e9;, Campus Virchow Clinic, Humboldt University, 13691 Berlin, Germany</aff><aff id="I2"><label>2</label>Hospital Pharmacy, Charit&#x000e9;, Campus Virchow Clinic</aff><pub-date pub-type="ppub"><year>1999</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2000</year></pub-date><volume>3</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">19th International Symposium on Intensive Care and Emergency Medicine</named-content></supplement><fpage>P106</fpage><lpage>P106</lpage><permissions><copyright-statement>Copyright &#x000a9;1999 Current Science Ltd</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Current Science Ltd</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/3/S1/P106"/><conference><conf-date>16-19 March 1999</conf-date><conf-name>19th International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Immunoparalysis, defined as a decreased level of human Ieukocyte antigen (HLA)-DR receptor expression on monocytes, correlates with the severity of septic shock and outcome [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>Hydrocortisone (HC) alters the immune response at almost all levels and is considered to suppress HLA-DR expression on monocytes. IFN-? as a potent activator of mononuclear phagocytes increases the ability of monocytes to express HLA-DR <italic>in vitro</italic> and <italic>in vivo.</italic> One of the aims of our study was to analyzeimmunosuppressive effects of HC stress-dose therapy in septic shock patients. Here we present results of an interim analysis of the first 20 patients enrolled in the study.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study was designed as a double blinded, randomized, cross-over, placebo-controlled trial in 40 patients. Patients who fulfilled the criteria for septic shock according to the Consensus Conference on Sepsis and Organ Failure [<xref ref-type="bibr" rid="B2">2</xref>] received a dose of 10 mg/h hydrocortisone after an initial loading dose of 100 mg, or placebo for 3 days. After 3 days, patients from the HC-group switched to the placebo-group and vice versa. Blood samples were obtained before the study and daily for a period of 6 days. A whole blood flow-cytometry analysis was performed to analyze monocyte HLA-DR antigen expression. Plasma IFN-? levels were measured by an enzyme-linked immunoassay.</p></sec><sec><title>Results</title><p>There were no striking differences in monocyte HLA-DR expression between patients who received HC or placebo (Fig. <xref ref-type="fig" rid="F1">1</xref>). However, compared to baseline values, a transient decrease of HI.A-DR expression was observed in the group which received HC early. INF-? increased in both groups after start of the study, but returned to baseline in the placebo-group on day 3 (Fig. <xref ref-type="fig" rid="F1">2</xref>). In the follow-up, INF-? did not further increase in the placebo-group but noticeably in the HC-group.</p></sec><sec><title>Conclusion</title><p>Stress-dose HC treatment did not induce immunoparalysis in patients with septic shock during the study period. HLA-DR expression remained almost constant over the period of the trial which we postulate to be due to HC-induced increase of INF-? synthesis.</p><fig id="F1" position="float"><label>Figures 1-2.</label><caption><p>Monocyte HLA-DR expression (Fig. <xref ref-type="fig" rid="F1">1</xref>) and IFN-gamma concentration (Fig. <xref ref-type="fig" rid="F1">2</xref>) in septic shock patients who received hydrocortisone therapy (see text). Day 0: before study. Data are presented as mean-values with SEM; <italic>n</italic> = 10 for each data point.</p></caption><graphic xlink:href="cc480-1"/></fig></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><name><surname>Hershman</surname><given-names>MJ</given-names></name><etal/><source>Injury</source><volume>19</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">3229842</pub-id><pub-id pub-id-type="doi">10.1016/0020-1383(88)90042-3</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Bone</surname><given-names>RC</given-names></name><etal/><source>Crit Care Med</source><year>1992</year><volume>20</volume><fpage>864</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">1597042</pub-id></mixed-citation></ref></ref-list></back></article>